Importance: Probiotics are frequently used by residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care), although the evidence on whether probiotics prevent infections and reduce antibiotic use in these settings is limited. Objective: To determine whether a daily oral probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 compared with placebo reduces antibiotic administration in care home residents. Design, Setting, and Participants: Placebo-controlled randomized clinical trial of 310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018. Interventions: Study participants were randomized to receive a daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 × 1010 to 1.6 × 1010) (n = 155), or daily matched placebo (n = 155), for up to 1 year. Main Outcomes and Measures: The primary outcome was cumulative antibiotic administration days for all-cause infections measured from randomization for up to 1 year. Results: Among 310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily data including study product use, antibiotic administration, and signs of infection) were available for 98.7% randomized to the probiotic group and 97.4% randomized to placebo. Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50). A total of 120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group). Hospitalizations accounted for 94 of the events in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events in the probiotic group and 32 of the events in the placebo group. Conclusions and Relevance: Among care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic administration for all-cause infections. These findings do not support the use of probiotics in this setting. Trial Registration: ISRCTN Identifier:16392920.
RCT Entities:
Importance: Probiotics are frequently used by residents in care homes (residential homes or nursing homes that provide residents with 24-hour support for personal care or nursing care), although the evidence on whether probiotics prevent infections and reduce antibiotic use in these settings is limited. Objective: To determine whether a daily oral probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 compared with placebo reduces antibiotic administration in care home residents. Design, Setting, and Participants: Placebo-controlled randomized clinical trial of 310 care home residents, aged 65 years and older, recruited from 23 care homes in the United Kingdom between December 2016 and May 2018, with last follow-up on October 31, 2018. Interventions: Study participants were randomized to receive a daily capsule containing a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 × 1010 to 1.6 × 1010) (n = 155), or daily matched placebo (n = 155), for up to 1 year. Main Outcomes and Measures: The primary outcome was cumulative antibiotic administration days for all-cause infections measured from randomization for up to 1 year. Results: Among 310 randomized care home residents (mean age, 85.3 years; 66.8% women), 195 (62.9%) remained alive and completed the trial. Participant diary data (daily data including study product use, antibiotic administration, and signs of infection) were available for 98.7% randomized to the probiotic group and 97.4% randomized to placebo. Care home residents randomized to the probiotic group had a mean of 12.9 cumulative systemic antibiotic administration days (95% CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (absolute difference, 0.9 days [95% CI, -3.25 to 5.05]; adjusted incidence rate ratio, 1.13 [95% CI, 0.79 to 1.63]; P = .50). A total of 120 care home residents experienced 283 adverse events (150 adverse events in the probiotic group and 133 in the placebo group). Hospitalizations accounted for 94 of the events in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events in the probiotic group and 32 of the events in the placebo group. Conclusions and Relevance: Among care home residents in the United Kingdom, a daily dose of a probiotic combination of Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp lactis BB-12 did not significantly reduce antibiotic administration for all-cause infections. These findings do not support the use of probiotics in this setting. Trial Registration: ISRCTN Identifier:16392920.
Authors: Patrick Alexander Wachholz; Vânia Dos Santos Nunes; Adriana Polachini do Valle; Alessandro Ferrari Jacinto; Paulo José Fortes Villas-Boas Journal: Age Ageing Date: 2018-07-01 Impact factor: 10.668
Authors: Biao Wang; Tammy Hylwka; Marek Smieja; Michael Surrette; Dawn M E Bowdish; Mark Loeb Journal: J Am Geriatr Soc Date: 2018-05-09 Impact factor: 5.562
Authors: Jonathan A Cook; Steven A Julious; William Sones; Lisa V Hampson; Catherine Hewitt; Jesse A Berlin; Deborah Ashby; Richard Emsley; Dean A Fergusson; Stephen J Walters; Edward C F Wilson; Graeme MacLennan; Nigel Stallard; Joanne C Rothwell; Martin Bland; Louise Brown; Craig R Ramsay; Andrew Cook; David Armstrong; Doug Altman; Luke D Vale Journal: BMJ Date: 2018-11-05
Authors: Eleri Owen-Jones; Rachel Lowe; Mark Lown; David Gillespie; Katy Addison; Tony Bayer; Philip C Calder; Jane Davies; Mina Davoudianfar; James Downs; Alison Edwards; Nick A Francis; Richard Fuller; Richard Hobbs; Kerenza Hood; Mandy Lau; Paul Little; Michael Moore; Victoria Shepherd; Helen Stanton; Alun Toghill; Mandy Wootton; Chris C Butler Journal: BMJ Open Date: 2019-06-20 Impact factor: 2.692
Authors: Sarah King; Daniel Tancredi; Irene Lenoir-Wijnkoop; Kelsie Gould; Hailey Vann; Grant Connors; Mary Ellen Sanders; Jeffrey A Linder; Andi L Shane; Dan Merenstein Journal: Eur J Public Health Date: 2019-06-01 Impact factor: 3.367
Authors: Vivian M Castro-Herrera; Mark Lown; Helena L Fisk; Eleri Owen-Jones; Mandy Lau; Rachel Lowe; Kerenza Hood; David Gillespie; F D Richard Hobbs; Paul Little; Christopher C Butler; Elizabeth A Miles; Philip C Calder Journal: Front Aging Date: 2021-03-17
Authors: David Schnadower; Karen J O'Connell; John M VanBuren; Cheryl Vance; Phillip I Tarr; Suzanne Schuh; Katrina Hurley; Alexander J Rogers; Naveen Poonai; Cindy G Roskind; Seema R Bhatt; Serge Gouin; Prashant Mahajan; Cody S Olsen; Elizabeth C Powell; Ken Farion; Robert E Sapien; Thomas H Chun; Stephen B Freedman Journal: Am J Gastroenterol Date: 2021-07-01 Impact factor: 12.045